24-LUN-138-BNT-PMC (BNT116-01): First-in-Human, Open label, Phase I Dose Confirmation Trial Evaluating The Safety, Tolerability, and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-Small Cell Lung Cancer

Grants and Contracts Details

StatusActive
Effective start/end date11/25/2411/25/26

Funding

  • BioNTech SE: $2.00